Delivery Order SPE2DB22D2007-SPE2DB25FJ5BR
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $2,793.70 and an ultimate completion date of September 5, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through open competition. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,793.70 firm fixed-price delivery order for 100-unit vials of Xeomin on July 11, 2025, with an ultimate completion date of August 1, 2025. The order will be fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. This competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger federal contract portfolio with the DLA. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Xeomin 100 Unit Vials with a ceiling value of $35,535.50 under a firm fixed-price contract. This non-set-aside award is scheduled for completion by October 8, 2025, with performance taking place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. The delivery order represents a competitively awarded procurement action sourced through the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $23,467.08 and a firm fixed price structure. This is a non-set-aside, competitively awarded contract with an ultimate completion date of October 9, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform the work at its Corporate Office location. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Xeomin 200 Unit Vials with a ceiling value of $2,793.70 and an ultimate completion date of October 2, 2025. This firm fixed price, competitively awarded delivery order carries no set-aside designation and represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is listed as Conshohocken, Pennsylvania, which...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Xeomin 100 unit vials valued at $6,704.88 with a firm fixed price structure. The order is scheduled for completion by August 19, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on May 9, 2025, for the supply of Xeomin 200 Unit Vials, with a ceiling value of $46,934.16 and a firm fixed price structure. This is a non-set-aside competitive award, with performance scheduled for completion by June 2, 2025, at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $9,118.20 to AmerisourceBergen Drug Corp for the supply of Xeomin 50 Unit Vials. The contract, issued on May 6, 2025, with an ultimate completion date of May 28, 2025, utilizes firm fixed pricing with no set-aside designation, indicating open and competitive procurement. Performance will take place at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Xeomin 50 unit vials valued at $10,941.84. This competitively awarded, non-set-aside contract is structured as a firm fixed price delivery order with a completion date of September 10, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. The delivery order falls under the...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $1,676.22 for 100-unit vials of Xeomin on May 9, 2025, with an ultimate completion date of June 2, 2025. This firm fixed-price contract, which carries no set-aside designation, will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The award represents a competitively procured delivery order under DLA's broader pharmaceutical supply chain, reflecting the agency's...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ5BRDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Xeomin 100 Unit Vials, with a ceiling value of $5,989.62 and an ultimate completion date of October 9, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under an open procurement process. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania, where the company serves as a critical pharmaceutical distributor for federal medical procurement needs. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. This comprehensive vehicle enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. Xeomin, a botulinum toxin product used in medical and aesthetic applications, represents one of many specialty medications that AmerisourceBergen delivers through its federal contract portfolio, which serves the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.0k | 9/18/25 |